[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100494930":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":30,"locations":37,"responsibleParty":53,"collaborators":24,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":24,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":24,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":40,"whyStopped":24,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Taiwan Bio Therapeutics Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Low dose allogeneic mesenchymal stromal cells","EXPERIMENTAL","Intracoronary administration 1.5 x 10\\^7 OmniMSC-AMI in first AMI patients who just underwent primary PCI",[13],"Biological: OmniMSC-AMI",{"label":15,"type":10,"description":16,"interventionNames":17},"High dose allogeneic mesenchymal stromal cells","Intracoronary administration 3.0 x 10\\^7 OmniMSC-AMI in first AMI who just underwent primary PCI",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","OmniMSC-AMI","10 anterior wall STEMI patients without cardiogenic shock will be enrolled into low dose group 1 (1.5 x 10\\^7 OmniMSC-AMI, n=5) and then high dose group 2 (3.0 x 10\\^7 OmniMSC-AMI, n=5).",[15,9],null,[26],{"name":27,"affiliation":28,"role":29},"Hon-Kan Yip, MD","Chang Gung Memorial Hospital","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Timothy Huang, PhD","CONTACT","02-26956382","512","timothy.huang@twbio-thera.com",[38],{"facility":39,"status":40,"city":41,"state":24,"zip":24,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Kaohsiung Chang Gung Memorial Hospital","RECRUITING","Kaohsiung City","Taiwan","TW",{"type":45,"coordinates":46},"Point",[47,48],120.31333,22.61626,{"lat":48,"lon":47},[51],{"name":27,"role":33,"phone":24,"phoneExt":24,"email":52},"han.gung@msa.hinet.net",{"type":54,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100494930","phase-1-intracoronary-administration-of-omnimsc-ami-for-acute-st-segment-elevation-myocardial-infarction-patients-100494930",false,"NCT05724576","Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients","Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention-Phase I Clinical Trial to Assess the Safety.","Inclusion Criteria:\n\n* Patents, with age ≤20 or ≤80 years old.\n* Fit to the definition of ST-elevation myocardial infarction (anterior myocardial infarction):\n\n  1. Chest pain onset.\n  2. 12-lead EKG:V1-V6 ≥ consecutive lead ST-segment elevation ≥1 mm.\n  3. TnT-I elevation.\n* Into emergency ≤ 6h upon AMI presentation.\n* Patients are willing to receive the treatment and sign the informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 20 or \\>80 years old.\n* History of\n\n  1. Malignancy.\n  2. Sepsis (abnormal WBC count elevation).\n  3. Hematologic disorder.\n  4. AIDS.\n  5. Advanced liver cirrhosis.\n  6. CKD stage 5 with Ccr \\\u003C15 ml\u002Fmin.\n* AMI occurrence \\> 6 hours\n* Non-first AMI.\n* Pregnancy or breastfeeding.\n* Prison.\n* Cancer treatment within 2 years.\n* Expected lifespan \\\u003C 6 months.\n* Non-suitable candidate evaluated by PI.\n* Participating in other clinical trials.","ALL","20 Years","80 Years",{"count":66,"type":67},10,"ESTIMATED","INTERVENTIONAL",[70],"PHASE1","This study will test the hypothesis intracoronary administration of OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells) just after finishing the primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients without cardiogenic shock is safe and may provide benefit on improving left ventricular ejection fraction (LVEF) during clinical follow-up.",[73],"Safety Issues",[75,76,77],"MSC","AMI","PCI","2025-06-04",{"date":80,"type":81},"2025-06-06","ACTUAL",{"date":83,"type":81},"2023-06-26",{"date":85,"type":67},"2026-03-01",{"name":5,"class":6},1]